Curasight A/S

Curasight A/S

Project management regarding communication in connection with the company’s IPO on the Spotlight Stock Market in 2020.

Client: Curasight
Type: IPO

Curasight’s Prospectus

Curasight’s Teaser

About Curasight

Curasight A/S is a clinical development company based in Copenhagen, Denmark. The company is a pioneer in the field of exploiting a novel Positron Emissions Tomography (PET) imaging platform targeting the urokinase-type plasminogen activator receptor (“uPAR”). The technology is expected to improve diagnosis and risk stratification in multiple cancer types.

READ MORE ON THEIR WEBSITE